secwatch / observer
8-K filed May 5, 2026, 7:59 PM ET ticker CPIX CIK 0001087294
M&A confidence high sentiment positive materiality 0.90

Cumberland Pharma enters $100M strategic transaction with Apotex, reports Q1 revenue $9.1M

CUMBERLAND PHARMACEUTICALS INC

item 2.02item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001087294-26-000046
form_type
8-K
ticker
CPIX
cik
0001087294
company_name
CUMBERLAND PHARMACEUTICALS INC
filed_at
2026-05-05T23:59:59+00:00
discovered_at
2026-05-14T18:02:31.932170+00:00
generated_at
2026-05-14T23:12:38.341277+00:00
sec_items
["2.02", "9.01"]
event_type
m_and_a
sentiment
positive
materiality_score
0.9
calibrated_materiality_score
0.9
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001087294-26-000046
json_url
https://secwatch.observer/filing/0001087294-26-000046.json
markdown_url
https://secwatch.observer/filing/0001087294-26-000046.md
text_url
https://secwatch.observer/filing/0001087294-26-000046.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1087294/000108729426000046/0001087294-26-000046-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1087294/000108729426000046/cpix-20260505.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

2923a815c5d9df7160069f91e9201e7278ecf2df

CUMBERLAND PHARMACEUTICALS INC reported three months ended March 31, 2026 results: revenue $9.1 million, net income net loss for the first quarter of 2026 was approximately $3.3 million, EPS $0.13 per share.

Pharmaceuticals Inc. (Nasdaq: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $9.1 million during the first quarter of 2026. Cumberland ended the quarter with $71.0 million in total assets, $49.7 million in liabilities and $21.6 million of shareholders’ equity. “We

SEC 8-K Item 2.02 confidence 0.9 SEC evidence

Comparable filings

TOMZ

TOMI reports Q1 revenue $1.65M, net loss $0.04/sh, and LOI to merge with Carbonium Core ($120M EV)

TOMI Environmental Solutions, Inc. May 8, 2026, 7:59 PM ET m_and_a Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: m_and_a

This filing

Pharmaceuticals Inc. (Nasdaq: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $9.1 million during the first quarter of 2026. Cumberland ended the quarter with $71.0 million in total assets, $49.7 million in liabilities and $21.6 million of shareholders’ equity. “We

Comparable filing

There can be no assurance that the Proposed Transaction will be consummated on the terms described or at all. 1 First Quarter 2026 Highlights: · Revenue Growth: Revenue of $1,654,000 for Q1 2026 represents a 5% increase versus Q1 2025 and a 67% sequential increase over Q4 2025, driven by strong equipment and Custom Engineered System (CES) sales. · Applicator

Filing page SEC filing

PANW

Palo Alto Networks Q3 revenue $3.0B (+31% YoY); NGS ARR $8.1B (+60% YoY)

Palo Alto Networks Inc June 2, 2026, 4:08 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 similar materiality

This filing

Pharmaceuticals Inc. (Nasdaq: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $9.1 million during the first quarter of 2026. Cumberland ended the quarter with $71.0 million in total assets, $49.7 million in liabilities and $21.6 million of shareholders’ equity. “We

Comparable filing

chief financial officer of Palo Alto Networks. Third Quarter Fiscal 2026 Financial Highlights • Total revenue for the fiscal third quarter 2026 grew 31% year over year to $3.0 billion. This includes $388 million from CyberArk and Chronosphere. • Next-Generation Security ARR for the fiscal third quarter 2026 grew 60% year over year to $8.1 billion. This

Filing page SEC filing

YSWY

Yesway reports Q1 net income $30.2M, Adjusted EBITDA $59.2M; introduces FY2026 outlook

Yesway, Inc. June 2, 2026, 7:35 AM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 similar materiality

This filing

Pharmaceuticals Inc. (Nasdaq: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $9.1 million during the first quarter of 2026. Cumberland ended the quarter with $71.0 million in total assets, $49.7 million in liabilities and $21.6 million of shareholders’ equity. “We

Comparable filing

On June 2, 2026, Yesway, Inc. issued a press release announcing its financial results for the three months ended March 31, 2026.

Filing page SEC filing

VSCO

Victoria's Secret Q1 sales up 15% to $1.56B, beats guidance; raises FY2026 outlook

Victoria's Secret & Co. June 2, 2026, 7:01 AM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 similar materiality

This filing

Pharmaceuticals Inc. (Nasdaq: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $9.1 million during the first quarter of 2026. Cumberland ended the quarter with $71.0 million in total assets, $49.7 million in liabilities and $21.6 million of shareholders’ equity. “We

Comparable filing

The Company reported net sales of $1.560 billion for the first quarter of 2026, an increase of 15% compared to net sales of $1.353 billion for the first quarter of 2025 and above the previously communicated guidance range of $1.490 billion to $1.525 billion. Total comparable sales for the first quarter of 2026 increased 13%. The Company reported operating income for the first quarter of 2026 of $76 million compared to operating income of $20 million in the first quarter of 2025. Net income was $48 million, or $0.56 per diluted share, for the first quarter of 2026 compared to net loss of $2 million, or $0.02 per diluted share, for the first quarter of 2025.

Filing page SEC filing

HPE

HPE Q2 FY26: record revenue $10.7B (+40%), raises FY26 guidance, introduces FY27 framework

Hewlett Packard Enterprise Co June 1, 2026, 4:09 PM ET earnings Items 1.01, 2.02, 5.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 similar materiality

This filing

Pharmaceuticals Inc. (Nasdaq: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $9.1 million during the first quarter of 2026. Cumberland ended the quarter with $71.0 million in total assets, $49.7 million in liabilities and $21.6 million of shareholders’ equity. “We

Comparable filing

gross margin, and non-GAAP diluted net EPS, as well as its highest-ever free cash flow generation for a second quarter. Second Quarter Fiscal 2026 Financial Results • Revenue : $10.7 billion, up 40% from the prior-year period • Gross margins : ◦ GAAP of 36.5%, up 810 basis points from the prior-year period and up 60 basis points sequentially ◦ Non-GAAP (1) of 36.9%,

Filing page SEC filing

CRDO

Credo Q4 revenue $437M (+157% YoY); guides Q1 $465-475M; CEO awarded 1.44M performance-based RSUs

Credo Technology Group Holding Ltd June 1, 2026, 4:08 PM ET earnings Items 2.02, 5.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 similar materiality

This filing

Pharmaceuticals Inc. (Nasdaq: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $9.1 million during the first quarter of 2026. Cumberland ended the quarter with $71.0 million in total assets, $49.7 million in liabilities and $21.6 million of shareholders’ equity. “We

Comparable filing

On June 1, 2026, Credo Technology Group Holding Ltd (the "Company") issued a press release announcing its financial results for the fiscal year ended May 2, 2026.

Filing page SEC filing

ACH

Accendra Health Q1 revenue $627.8M, adj. EBITDA $58.4M; >$1.5B debt optimization

ACCENDRA HEALTH INC/VA/ May 11, 2026, 7:59 PM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 similar materiality

This filing

Pharmaceuticals Inc. (Nasdaq: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $9.1 million during the first quarter of 2026. Cumberland ended the quarter with $71.0 million in total assets, $49.7 million in liabilities and $21.6 million of shareholders’ equity. “We

Comparable filing

Commission this morning. ​ Details on First Quarter 2026 Results ​ ​ First Quarter Results (1) ​ ($ in millions, except per share data) ​ ​ ​ 1Q26 ​ ​ ​ 1Q25 Net Revenue ​ $ 627.8 ​ $ 673.9 ​ ​ ​ ​ ​ ​ ​ Loss from continuing operations, net of tax, GAAP ​ $ (6.5) ​ $ (3.8) Adj. net (loss) income from continuing operations, Non-GAAP ​ $ (3.1) ​ $ 23.2 ​ ​ ​

Filing page SEC filing

LQDA

Liquidia Q1 2026 net income $53M vs $38M loss YoY; YUTREPIA sales $130M

Liquidia Corp May 11, 2026, 7:59 PM ET earnings Items 2.02, 8.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 similar materiality

This filing

Pharmaceuticals Inc. (Nasdaq: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $9.1 million during the first quarter of 2026. Cumberland ended the quarter with $71.0 million in total assets, $49.7 million in liabilities and $21.6 million of shareholders’ equity. “We

Comparable filing

First Quarter 2026 Financial Results YUTREPIA sales led to the company’s third consecutive quarter of profitability with net income of $52.9 million and positive non-GAAP adjusted EBITDA of $71.2 million in the first quarter of 2026. Cash and cash equivalents totaled $222.8 million as of March 31, 2026, compared to $190.7 million as of December 31, 2025. Product sales, net, were $129.9 million for the three months ended March 31, 2026.

Filing page SEC filing

Source: SEC EDGAR
accession 0001087294-26-000046
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.